Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Trial of an Encapsulated Cell Therapy Product in Locally Advanced, Inoperable Pancreatic Cancer (LAPC)

Trial Profile

A Phase IIb Trial of an Encapsulated Cell Therapy Product in Locally Advanced, Inoperable Pancreatic Cancer (LAPC)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifosfamide (Primary) ; Microencapsulated CYP2B1-expressing cells+ifosfamide PharmaCyte Biotech (Primary) ; Capecitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PharmaCyte Biotech
  • Most Recent Events

    • 14 Oct 2019 According to a PharmaCyte Biotech media release, the company announced that its its partner, Austrianova Singapore (Austrianova), has completed the first of two staggered and back to back manufacturing runs for the production of clinical trial product which will be used in this trial.
    • 12 Sep 2019 According to a PharmaCyte Biotech media release, the shareholder update conference call scheduled for next week will cover the companys preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration to treat locally advanced, inoperable pancreatic cancer.
    • 10 Jun 2019 According to a PharmaCyte Biotech media release, the company intends to file an IND for Microencapsulated-CYP2B1-expressing-cells+ifosfamide for the treatment of pancreatic cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top